Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A 16-year-old girl presented with a high fever that had persisted for more than 4 weeks. Computed tomography revealed a 4-cm mass in the left adrenal gland. Clinically, there were no obvious symptoms of adrenal hormone excess; however, serum interleukin-6 (IL-6) and C-reactive protein levels were significantly elevated. After laparoscopic left adrenalectomy, the fever subsided, and her IL-6 level normalized. The tumor was pathologically diagnosed as adrenocortical carcinoma (ACC), with a Weiss score of 5/9. The tumor cells were immunoreactive for IL-6. To our knowledge, this is the first case report of symptomatic IL-6-producing ACC that initially presented with a persistent fever.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12393916 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.4599-24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Iron Oxide Nanoparticle Uptake, Toxicity, and Steroidogenesis in Adrenocortical Carcinoma Cells Using a Multicellular in vitro Model.
Int J Nanomedicine
September 2025
Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway, Ireland.
Introduction: Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis, limited treatment options, and high recurrence rates. Surgery and mitotane-based chemotherapy remain the standard of care, and new treatment strategies are needed. Iron oxide nanoparticles (IONPs) offer promise as theranostic agents due to their modifiability for selective uptake and imaging.
View Article and Find Full Text PDFGiant non-functioning adrenocortical carcinoma: a case report and literature review.
Chin Clin Oncol
August 2025
Department of Surgery, King Fahd Hospital, Jeddah, Saudia Arabia.
Background: Adrenocortical carcinoma (ACC) is a rare and highly aggressive malignancy, ranking as the second most aggressive endocrine tumor after anaplastic thyroid cancer. ACC typically presents symptoms caused by the tumor mass and less often with signs of excess hormones. Due to its rarity, the diagnosis and management of ACC pose significant challenges, with limited clinical guidelines, a lack of large-scale randomized studies, and a paucity of treatment experience.
View Article and Find Full Text PDFCoexistence of low-grade pulmonary mucinous epithelioid carcinoma and metastatic adrenal sarcomatoid carcinoma: a rare case report with BRAF p.V600E-driven molecular insights and clinical challenges.
Front Oncol
August 2025
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Introduction: Pulmonary mucinous epithelioid carcinoma (PMEC) is a rare malignancy that typically progresses slowly and has a favorable prognosis. In contrast, adrenal sarcomatoid carcinoma (ASC) is an aggressive and uncommon cancer with poor outcomes. The coexistence of low-grade PMEC and metastatic ASC is exceedingly rare and presents unique clinical challenges, with limited treatment options and poor prognosis.
View Article and Find Full Text PDFNon-functional oncocytic adrenocortical carcinoma: Case report with clinicopathologic and surgical correlation.
Urol Case Rep
September 2025
Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Oncocytic adrenocortical carcinoma (OACC) is a rare variant of adrenocortical carcinoma composed predominantly of oncocytic cells. We present the case of a 45-year-old female with a large, non-functional left adrenal mass diagnosed as OACC. Imaging revealed a well-defined, vascular, heterogeneously enhancing mass without metastasis.
View Article and Find Full Text PDFFrontiers in Systemic Therapy for Unresectable or Metastatic Adrenocortical Carcinoma: Harnessing Novel Therapeutic Approaches.
Clin Med Insights Oncol
August 2025
Division of Hematology/Oncology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Adrenocortical carcinoma is a rare, aggressive endocrine malignancy with limited effective systemic therapy options and an overall poor prognosis for unresectable or metastatic disease. Chemotherapy and mitotane are the traditional systemic therapies of choice. More recently, as drug development in oncology has shifted away from chemotherapy, a host of therapeutic approaches targeting novel mechanisms of action has been studied in adrenocortical carcinoma.
View Article and Find Full Text PDF